Supernus Pharmaceuticals Announces Proposed Merger with Indivior

What Happened
Supernus Pharmaceuticals, Inc. announced on August 3, 2026 that it published a LinkedIn post and distributed employee communications (an email from President & CEO Jack A. Khattar and an employee presentation) regarding the proposed "merger of equals" with Indivior Pharmaceuticals Inc. The company said Indivior intends to file a Form S-4 with the SEC that will include a joint proxy statement/prospectus for the transaction and that a definitive joint proxy statement/prospectus will be sent to both companies’ stockholders when available. The 8-K also reiterates standard forward-looking statement disclosures and material risks related to the proposed transaction.

Key Details

• Date of communications: August 3, 2026 (LinkedIn post, employee email from CEO Jack A. Khattar, and employee presentation).
• Transaction: Proposed merger of equals between Supernus and Indivior; Indivior to file Form S-4 including the joint proxy statement/prospectus.
• Shareholder process: A definitive joint proxy statement/prospectus will be mailed to Indivior’s and Supernus’ stockholders when available; investors are urged to read it.
• Material risks highlighted: possibility the merger may not close, need for stockholder and regulatory approvals, fixed exchange ratio (not adjusted for market price changes), additional indebtedness to fund a Special Dividend, integration risks, and potential litigation.

Why It Matters
This filing signals a material corporate transaction that could significantly affect Supernus’ and Indivior’s shareholders. The outcome depends on approvals and other conditions described in the forthcoming joint proxy statement/prospectus; until that document is filed and reviewed, investors should consider the listed risks and await the formal disclosure before making voting or investment decisions.